Physica Medica: European Journal of Medical Physics
Volume 25, Issue 1 , Pages 12-24 , March 2009

On the impact of functional imaging accuracy on selective boosting IMRT

  • Y. Kim

      Affiliations

    • Department of Radiation Oncology, University of Iowa, Iowa City, IA, USA
    • ,
  • W.A. Tomé

      Affiliations

    • Department of Human Oncology, School of Medicine and Public Health, University of Wisconsin, K4/314 CSC, 600 Highland Avenue, Madison, WI 53792, USA
    • Department of Medical Physics, School of Medicine and Public Health, University of Wisconsin, K4/314 CSC, 600 Highland Avenue, Madison, WI 53792, USA
    • Corresponding Author InformationCorresponding author. Department of Human Oncology, School of Medicine and Public Health, University of Wisconsin, K4/314 CSC, 600 Highland Avenue, Madison, WI 53792, USA. Tel.: +1 608 263 8510; fax: +1 608 263 9947.

Received 4 July 2007 ,Revised 8 November 2007 ,Accepted 3 December 2007.

References 

  1. Chao KSC, Bosch WR, Mutic S, Lewis JS, Dehdashti F, Mintun MA, et al. A novel approach to overcome hypoxic tumour resistance: Cu-ATSM-guided intensity-modulated radiation therapy. Int J Radiat Oncol Biol Phys. 2001;49(4):1171–1182
  2. De Meerleer G, Villeirs G, Bral S, Paelinck L, De Gersem W, Dekuyper P, et al. The magnetic resonance detected intraprostatic lesion in prostate cancer: planning and delivery of intensity-modulated radiotherapy. Radiother Oncol. 2005;75(3):325–333
  3. van Lin EN, Fütterer JJ, Heijmink SW, van der Vight LP, Hoffmann AL, van Kollenburg P, et al. IMRT boost dose planning on dominant intraprostatic lesions: gold marker-based three-dimensional fusion of CT with dynamic contrast-enhanced and 1H-spectroscopic MRI. Int J Radiat Oncol Biol Phys. 2006;65(1):291–303
  4. Tomé WA, Fowler JF. Selective boosting of tumor subvolumes. Int J Radiat Oncol Biol Phys. 2000;48(2):593–599
  5. Kim Y, Tomé WA. Risk-adaptive optimization: selective boosting of high-risk tumor subvolumes. Int J Radiat Oncol Biol Phys. 2006;66(5):1528–1542
  6. Popple RA, Ove R, Shen S. Tumor control probability for selective boosting of hypoxic subvolumes, including the effect of reoxygenation. Int J Radiat Oncol Biol Phys. 2002;54(3):921–927
  7. Ling CC, Humm J, Larson S, Amols H, Fuks Z, Leibel S, et al. Towards multidimensional radiotherapy (MD-CRT): biological imaging and biological conformality. Int J Radiat Oncol Biol Phys. 2000;47(3):551–560
  8. Bentzen SM. Theragnostic imaging for radiation oncology: dose-painting by numbers. Lancet Oncol. 2005;6(2):112–117
  9. Dawson LA, Sharpe MB. Image-guided radiotherapy: rationale, benefits, and limitations. Lancet Oncol. 2006;7(10):848–858
  10. Song W, Schaly B, Bauman G, Battista J, Van Dyk J. Image-guided adaptive radiation therapy (IGART): Radiobiological and dose escalation considerations for localized carcinoma of the prostate. Med Phys. 2005;32(7):2193–2203
  11. Brahme A. Optimized radiation therapy based on radiobiological objectives. Semin Radiat Oncol. 1999;9(1):35–47
  12. Wolbarst AB, Sternick ES, Curran BH, Dritschilo A. Optimized radiotherapy treatment planning using the complication probability factor (CPF). Int J Radiat Oncol Biol Phys. 1980;6(6):723–728
  13. Wang XH, Mohan R, Jackson A, Leibel SA, Fuks Z, Ling CC. Optimization of intensity-modulated 3D conformal treatment plans based on biological indices. Radiother Oncol. 1995;37(2):140–152
  14. Pickett B, Vigneault E, Kurhanewicz J, Verhey L, Roach M. Static field intensity modulation to treat a dominant intraprostatic lesion to 90 Gy compared to seven field 3 dimentional radiotherapy. Int J Radiat Oncol Biol Phys. 1999;44(4):921–929
  15. Xia P, Pickett B, Vigneault E, Verhey LJ, Roach M. Forward or inversely planned segmental multileaf collimator IMRT and sequential tomotherapy to treat multiple dominant intraprostatic lesions of prostate cancer to 90 Gy. Int J Radiat Oncol Biol Phys. 2001;51(1):244–254
  16. Grégoire V, Bol A, Geets X, Lee J. Is PET-based treatment planning the new standard in modern radiotherapy? The head and neck paradigm. Semin Radiat Oncol. 2006;16(4):232–238
  17. Apisarnthanarax S, Chao KSC. Current imaging paradigms in radiation oncology. Radiat Res. 2005;163(1):1–25
  18. Jerusalem G, Hustinx R, Beguin Y, Fillet G. PET scan imaging in oncology. Eur J Cancer. 2003;39(11):1525–1534
  19. McNeal JE, Redwine EA, Freiha FS, Stamey TA. Zonal distribution of prostatic adenocarcinoma: correlation with histopathologic pattern and direction of spread. Am J Surg Pathol. 1988;12(12):897–906
  20. Pollack A, Zagars GK, Starkschall G, Antolak JA, Lee JJ, Huang E, et al. Prostate cancer radiation dose response: Results of the M.D. Anderson phase III randomized trial. Int J Radiat Oncol Biol Phys. 2002;53(5):1097–1105
  21. Burman CM, Zelefsky MJ, Leibel SA. Treatment planning, dose delivery, and outcome of IMRT for localized prostate cancer. In:  Hellman S, et al. editor. A practical guide to intensity-modulated radiation therapy. Madison, WI: Medical Physics Publishing; 2003;p. 169–190
  22. Bentzen SM, Tucker SL. Quantifying the position and steepness of radiation dose-response curves. Int J Radiat Biol. 1997;71(1):531–542
  23. Suit HD, Shalek RJ, Wette R. Radiation response of C3H mouse mammary carcinoma evaluated in terms of cellular radiation sensitivity. In: Cellular Radiation Biology. Baltimore: Williams & Wilkins; 1965;p. 514–530
  24. Levegrün SA, Jackson MJ, Zelefsky ES, Venkatraman ES, Skwarchuk MW, Schlegel W, et al. Risk group dependence of dose-response for biopsy outcome after three-dimensional conformal radiation therapy of prostate cancer. Radiother Oncol. 2002;63(1):11–26
  25. Goitein M, Niemierko A, Okunieff P. The probability of controlling an inhomogeneously irradiated tumor. In: Kaulner K, Carey B, Crellin A, editors. Quantitative imaging in oncology. Proceedings of the 19th LH Gray Conference. London: British Institute of Radiology; 1995. p. 25–32.
  26. Lyman JT. Complication probability as assessed from dose-volume histograms. Radiat Res. 1985;8:S13–S19
  27. Niemierko A. A generalized concept of equivalent uniform dose (EUD). Med Phys. 1999;26(6):1100
  28. Kutcher GJ, Burman C. Calculation of complication probability factors for non-uniform normal tissue irradiation: the effective volume method. Int J Radiat Oncol Biol Phys. 1989;16(6):1623–1630
  29. Rancati T, Fiorino C, Gagliardi G, Cattaneo GM, Sanguineti G, Borca VC, et al. Fitting late rectal bleeding data using different NTCP models: results from an Italian multi-centric study (AIROPROS0101). Radiother Oncol. 2004;73(1):21–32
  30. Tucker SL, Dong L, Cheung R, Johnson J, Mohan R, Huang EH, et al. Comparison of rectal dose-wall histogram versus dose-volume histogram for modeling the incidence of late rectal bleeding after radiotherapy. Int J Radiat Oncol Biol Phys. 2004;60(5):1589–1601
  31. Munro TR, Gilbert CW. The relation between tumour lethal doses and the radiosensitivity of tumour cells. Br. J Radiol. 1961;34:246–251
  32. Marks LB, Carroll PR, Dugan TC, Anscher MS. The response of the urinary bladder, urethra, and ureter to radiation and chemotherapy. Int J Radiat Oncol Biol Phys. 1995;31(5):1257–1280
  33. Zietman AL, DeSilvio M, Slater JD, Rossi CJ, Miller DW, Adams JA, et al. Comparison of conventional dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: a randomized controlled trial. JAMA. 2005;294:1274–1276
  34. Pollack A, Zagars GK, Smith LG, Lee JJ, von Eschenbach AC, Antolak JA, et al. Preliminary results of a randomized radiotherapy dose-escalation study comparing 70 Gy with 78 Gy for prostate cancer. J Clin Oncol. 2000;18(23):3904–3911
  35. Sathya JR, Davis IR, Julian JA, Guo Q, Daya D, Dayes IS, et al. Randomized trial comparing iridium implant plus external-beam radiation therapy with external-beam radiation therapy alone in node-negative locally advanced cancer of the prostate. J Clin Oncol. 2005;23(6):1192–1199
  36. Lukka H, Hayter C, Julian JA, Warde P, Morris WJ, Gospodarowicz M, et al. Randomized trial comparing two fractionation schemes for patients with localized prostate cancer. J Clin Oncol. 2005;23(25):6132–6138
  37. Jacob R, Hanlon AL, Horwitz EM, Movasas B, Uzzo RG, Rollack A. The relationship of increasing radiotherapy dose to reduced distant metastases and mortality in men with prostate cancer. Cancer. 2004;100(3):538–543
  38. Gambhir SS, Czernin J, Schwimmer J, Silverman DH, Coleman RE, Rhelps ME. A tabulated summary of the FDG PET literature. J Nucl Med. 2001;42(5 suppl):1S–93S
  39. Pieterman RM, van Putten JW, Meuzelaar JJ, Mooyaart EL, Vaalburg W, Koëter GH, et al. Preoperative staging of non-small-cell lung cancer with positron-emission tomography. N Engl J Med. 2000;343(4):254–261
  40. Staib L, Schirrmeister H, Reske SN, Beger HG. Is 18F-fluorodeoxyglucose positron emission tomography in recurrent colorectal cancer a contribution to surgical decision making?. Am J Surg. 2000;180(1):1–5
  41. Scheidler J, Hricak H, Vigneron DB, Yu KK, Sokolov DL, Huang LR, et al. Prostate cancer: localization with three-dimensional proton MR spectroscopic imaging—clinicopathologic study. Radiology. 1999;213(2):473–480
  42. Wefer AE, Hricak H, Vigneron DB, Coakley FV, Lu Y, Wefer J, et al. Sextant localization of prostate cancer: Comparison of sextant biopsy, magnetic resonance imaging and magnetic resonance spectroscopic imaging with step section histology. J Urol. 2000;164(2):400–404
  43. Buck AK, Schirmeister H, Hetzel M, Von Der Heide M, Halter G, Glatting G, et al. 3-Deoxy-3-(18F)fluorothymidine-positron emission tomography for non-invasive assessment of proliferation in pulmonary nodules. Cancer Res. 2002;62(12):3331–3334
  44. Yap CS, Czernin J, Fishbein MC, Cameron RB, Schiepers C, Phelps ME, et al. Evaluation of thoracic tumors with 18F-fluorothymidine and 18F-fluorodeoxyglucose-positron emission tomography. Chest. 2006;129(2):393–401
  45. Nestle U, Kremp S, Grosu AL. Practical integration of [18F]-FDG-PET and PET-CT in the planning of radiotherapy for non-small cell lung cancer (NSCLC): the technical basis, ICRU-target volumes, problems, perspectives. Radiother Oncol. 2006;81(2):209–225
  46. Yuan H, Schroeder T, Bowsher JE, Hedlund LW, Wong T, Dewhirst MW. Intertumoral differences in hypoxia selectivity of the PET imaging agent 64Cu(II)-diacetyl-bis (N4-Methylthiosemicarbazone). J Nucl Med. 2006;47(6):989–998
  47. Smit WG, Helle PA, Van Putten WL, Wijnmaalen AJ, Seldenrath JJ, van der Werf-Messing BH. Late radiation damage in prostate cancer patients treated by high dose external radiotherapy in relation to rectal dose. Int J Radiat Oncol Biol Phys. 1990;18(1):23–29
  48. Patel RR, Orton N, Tomé WA, Chappell R, Ritter MA. Rectal dose sparing with a balloon catheter and ultrasound localization in conformal radiation therapy for prostate cancer. Radiother Oncol. 2003;67(3):285–294
  49. Fiorino C, Sanguineti G, Cozzarini C, Fellin G, Foppiano F, Menegotti L, et al. Rectal dose-volume constraints in high-dose radiotherapy of localized prostate cancer. Int J Radiat Oncol Biol Phys. 2003;57(4):953–962
  50. Jackson A, Skwarchuk MW, Zelefsky MJ, Cowen DM, Venkatraman ES, Levegrün S, et al. Late rectal bleeding after conformal radiotherapy of prostate cancer (II): Volume effects and dose-volume histograms. Int J Radiat Oncol Biol Phys. 2001;49(3):685–698
  51. Fiorino C, Cozzarini C, Vavassori V, Sanguineti G, Bianchi C, Cattaneo GM, et al. Relationships between DVHs and late rectal bleeding after radiotherapy for prostate cancer: analysis of a large group of patients pooled from three institutions. Radiother Oncol. 2002;64(1):1–12
  52. Declich F, Masi L, Menegotti L, Stasi M, Fiorino C, Manzoni A. Comparing rectal DVH calculation with four commercial treatment planning systems by means of the AAPM TG23 18MV unit. Radiother Oncol. 2002;64(suppl 1):S318

PII: S1120-1797(07)00137-8

doi: 10.1016/j.ejmp.2007.12.001

Physica Medica: European Journal of Medical Physics
Volume 25, Issue 1 , Pages 12-24 , March 2009

Article Tools

* Image Usage & Resolution